METTL8 links mt-tRNA m3C modification to the HIF1α/RTK/Akt axis to sustain GBM stemness and tumorigenicity

• Published in: Cell death & disease 2024-05, Vol.15 (5), p.338-13, Article 338
• Main Authors: Lee, Bernice Woon Li, Chuah, You Heng, Yoon, Jeehyun, Grinchuk, Oleg V., Liang, Yajing, Hirpara, Jayshree L., Shen, Yating, Wang, Loo Chien, Lim, Yan Ting, Zhao, Tianyun, Sobota, Radoslaw M., Yeo, Tseng Tsai, Wong, Andrea Li Ann, Teo, Kejia, Nga, Vincent Diong Weng, Tan, Bryce Wei Quan, Suda, Toshio, Toh, Tan Boon, Pervaiz, Shazib, Lin, Zhewang, Ong, Derrick Sek Tong
• Format: Article
• Language: English
• Subjects: 13/100; 631/337/1645/2570; 631/67/1922; 64; 64/60; 96; 96/1; 96/95; AKT protein; Alternative splicing; Antibodies; Biochemistry; Biomedical and Life Sciences; Cell Biology; Cell Culture; Cell fate; Cell self-renewal; Chromatin; Glioblastoma; Glioma; Glioma cells; Histones; Immunology; Isoforms; Kinases; Life Sciences; Malignancy; Mitochondria; Nucleoli; Protein-tyrosine kinase receptors; Transfer RNA; tRNA; tRNA Ala; Tumorigenicity
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-024-06718-2

Epitranscriptomic RNA modifications are crucial for the maintenance of glioma stem cells (GSCs), the most malignant cells in glioblastoma (GBM). 3-methylcytosine (m 3 C) is a new epitranscriptomic mark on RNAs and METTL8 represents an m 3 C writer that is dysregulated in cancer. Although METTL8 has an established function in mitochondrial tRNA (mt-tRNA) m 3 C modification, alternative splicing of METTL8 can also generate isoforms that localize to the nucleolus where they may regulate R-loop formation. The molecular basis for METTL8 dysregulation in GBM, and which METTL8 isoform(s) may influence GBM cell fate and malignancy remain elusive. Here, we investigated the role of METTL8 in regulating GBM stemness and tumorigenicity. In GSC, METTL8 is exclusively localized to the mitochondrial matrix where it installs m 3 C on mt-tRNA Thr/Ser(UCN) for mitochondrial translation and respiration. High expression of METTL8 in GBM is attributed to histone variant H2AZ-mediated chromatin accessibility of HIF1α and portends inferior glioma patient outcome. METTL8 depletion impairs the ability of GSC to self-renew and differentiate, thus retarding tumor growth in an intracranial GBM xenograft model. Interestingly, METTL8 depletion decreases protein levels of HIF1α, which serves as a transcription factor for several receptor tyrosine kinase (RTK) genes, in GSC. Accordingly, METTL8 loss inactivates the RTK/Akt axis leading to heightened sensitivity to Akt inhibitor treatment. These mechanistic findings, along with the intimate link between METTL8 levels and the HIF1α/RTK/Akt axis in glioma patients, guided us to propose a HIF1α/Akt inhibitor combination which potently compromises GSC proliferation/self-renewal in vitro. Thus, METTL8 represents a new GBM dependency that is therapeutically targetable.